Navigation Links
New Data Demonstrate Longer-Term Safety Profile of Esbriet®
Date:9/26/2011

as similar to that observed among pirfenidone-treated patients in the CAPACITY studies.

About CAPACITY

The CAPACITY program was comprised of two multinational, double-blind, placebo-controlled Phase 3 studies (Study 004 and Study 006) that were conducted simultaneously with 779 IPF patients (aged 40-80 years) across 110 centers in Australia, Europe and North America. Patients were randomly assigned to receive oral Esbriet (1197 or 2403 mg/day) or placebo for a minimum of 72 weeks to evaluate the impact of Esbriet in reducing lung function deterioration in IPF patients.

CAPACITY results demonstrated that treatment with Esbriet:

  • Positively impacted key measures of lung function in IPF patients, including a significant reduction in the decline of Forced Vital Capacity (FVC).
  • Led to a significant reduction in the decline of Six-Minute Walk Test (6MWT) distance, an indication of improved pulmonary function.
  • In addition, an independent meta-analysis of progression free survival suggested a 30 percent lower risk of death or disease progression.(2)

About Esbriet

Esbriet (pirfenidone) is an orally active drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key role in fibrosis. It also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.

On February 28, 2011, the European Commission (EC) granted marketing authorization for Esbriet in adults for the treatment of mild to moderate IPF. The approval authorizes marketing of Esbriet in all 27 EU member states. Esbriet has since been approved for marketing in Norway and Iceland. It is now available in Germany and is scheduled to be available in France, Italy and Spain during the first half of 2012 and in the United Kingdom duri
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
2. Inovio Pharmaceuticals Completes PENNVAX™-B HIV Vaccine Phase I Study, Demonstrates Best-in-Class T-Cell Immune Responses
3. Germgard Lighting Demonstrates the Worlds Most Effective Hand Sterilizer to Protect Against Contagion
4. NIH-Funded Study Demonstrates That Patients Receiving New CPR Devices (ResQPOD® and ResQPump™) and Cooling Have Improved Long-Term Brain Function Following Cardiac Arrest
5. New Digital Linear Accelerator Control System Demonstrates Treatment Time Savings of Up to 30 Percent
6. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
7. Inovio Pharmaceuticals Demonstrates Positive Immune Responses in Phase I Clinical Trial of SynCon™ H5N1 Influenza Vaccine and Launches Multi-Subtype Influenza Vaccine Phase I
8. New Research Demonstrates High Prevalence of Sexually Transmitted Disease Trichomonas Vaginalis and Potential of New Molecular Test to Improve Detection
9. Topaz Pharmaceuticals Ivermectin Cream In Vitro Data Demonstrates Activity Against Head Lice Eggs
10. Halozymes Ultrafast Insulin Demonstrates Reduced Variability of Insulin Absorption for Type 1 Diabetes Patients Using Insulin Pumps
11. CureFAKtor Pharmaceuticals Demonstrates that Novel Focal Adhesion Kinase (FAK) Inhibitors Decrease Pancreatic Cancer Tumor Blood Flow and Reduce Blood Vessel Density
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  CryoLife, Inc. (NYSE: ... tissue processing company focused on cardiac and vascular surgery, ... President and Chief Executive Officer, has been elected to ... Steven G. Anderson , Executive Chairman ... has proven to be an excellent leader who is ...
(Date:10/22/2014)... 2014  Early symptoms of diabetic eye and ... new technology, coupled with yearly, comprehensive eye exams, ... detection of eye diseases, including those associated with ... left untreated, these diseases can potentially lead to ... Recently, optometric researchers have deployed a new tool ...
(Date:10/22/2014)... 2014 InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) ... revolutionizing spinal cord injury (SCI) treatment with their novel ... in tissue regrowth in the spinal cord area when ... FDA approved polymer, the scaffold ultimately breaks down to ... human body. NVIV has recently attracted significant investor attention ...
Breaking Medicine Technology:Pat Mackin Joins CryoLife Board of Directors 2Pat Mackin Joins CryoLife Board of Directors 3Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3
... 2a Clinical Trial at UCSD, NOVATO, ... or the "Company") (OTC Bulletin Board:,RPTP), today ... (the,"Agreement") with the University of California, San ... trial to evaluate a delayed-release preparation,of cysteamine ...
... Corporation, a,Georgia-based biotech company, announced today a ... collaboration with Cato Research Ltd.,its global contract ... will help support continued development of Abeome,s ... vastly improves the development of,monoclonal antibodies and ...
Cached Medicine Technology:Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 2Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 3Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 4Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease 5Abeome and Cato Research to Collaborate on Ovarian Cancer Therapeutic 2
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Hay House is ... Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written by ... Yoga & Recovery. This book is meant to help ... a life of recovery. , Recovery 2.0 is not ... Steps; Recovery 2.0 is a guide for what comes next. ...
(Date:10/22/2014)... (PRWEB) October 22, 2014 Best Cheap ... in the world. The site has recently announced that ... hosting supplier for people from around the world. , ... in operation today and is providing various kinds of ... the company insists on offering excellent customer service and ...
(Date:10/22/2014)... October 22, 2014 Although there are only 24 ... for many people who have trouble finding time within their busy ... exercise for long periods of time to get in shape. Here ... while on the go. , Change Up Your Commute , ... work to add some exercise into your daily routine. If you ...
(Date:10/22/2014)... 2014 Akeso Biomedical, Inc. , ... treatment of bacterial infections, microbial biofilms, and chronic wounds, ... board of directors. , Dr. Sinskey ... The Massachusetts Institute of Technology, or MIT. He has ... Dr. Sinskey also holds positions as Co-Director of the ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2
... access to serve offshore health needs by video ... first full-service offshore medical product using video telemedicine, ... industry - securing physician staffing for 24/7/365 services ... services are provided by emergency medicine and internal ...
... Co., Inc., (NYSE Amex: TPI ), a ... in Chengdu, China, today,announced that management will hold a ... 11:00 a.m. EDT on Friday, May 15, 2009. Financial,results ... market closes. , Interested parties ...
... behalf of 1.275 million Americans living with spinal cord injurySHORT ... Foundation today announced Matthew Reeve, son of Christopher Reeve and ... will run the 2009 ING New York City Marathon. Running ... compete on behalf of the 1.275 million Americans living with ...
... 50 with prostate cancer, undergoing a radical prostatectomy can ... a new study from Henry Ford Hospital. , Results ... show that the surgical procedure improves the 5-, 10-, ... with other standard treatments such as radiotherapy or watchful ...
... embryonic stem cells are recognized as a potential treatment ... injury (SCI). However, in studies using embryonic stem cells ... been the development of tumors following transplantation. , ... (Vol. 18 No.1), a team of Japanese researchers ...
... Palomar Medical Technologies, Inc. (Nasdaq: PMTI ), ... cosmetic treatments, announced today that it has entered into ... leading manufacturer of solid state lasers, for Quantel,s SINON(TM) ... United States and Canada.The SINON Q-switched ruby laser was ...
Cached Medicine News:Health News:The Doctor Is In, Around the Clock 2Health News:The Doctor Is In, Around the Clock 3Health News:Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 2Health News:Matthew Reeve to Run 2009 ING New York City Marathon for Team Reeve 3Health News:Surgery improves survival for prostate cancer patients younger than 50 2Health News:Bone marrow stem cell co-transplantation prevents embryonic stem cell transplant-associated tumors 2Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 2Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 3Health News:Palomar Medical to Market Quantel's SINON Tattoo Removal Laser in the United States and Canada 4
... to end transcription services. Zodiac offers ... be either submitted over the phone ... call 24 hours a day, 7 ... be recorded on a digital handheld ...
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
... Catering to the special needs ... Infant ThermoWrap™ protects the littlest ... their most vulnerable by providing ... continuous management of an infants ...
The under-patient design of the pediatric full access blanket warms even the tiniest patients while allowing full access for surgeons and staff....
Medicine Products: